🇺🇸 FDA
Patent

US 10570214

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

granted A61KA61K2039/505A61K2239/31

Quick answer

US patent 10570214 (Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K2239/47